Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 3/20 | 0.49 |
| ▸ | DRD5 | P21918 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480307 | 0.89 | MAOA (0.46) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL3896970 | 0.85 | MAOA (0.49) | MAOAMAOBSLC6A4CA7GAA | |
| SCHEMBL3906143 | 0.84 | MAOA (0.56) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL3900962 | 0.84 | MAOA (0.56) | MAOAMAOBSLC6A4DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL10350988 | 0.84 | MAOA (0.56) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL6248353 | 0.83 | ALDH1A1 (0.45) | MAOAMAOBSLC6A4MAPTTSHR | |
| SCHEMBL3907217 | 0.81 | ESR1 (0.55) | CA7MEN1KMT2APDE4D | |
| SCHEMBL3903162 | 0.79 | MAOB (0.48) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL11169272 | 0.78 | MAOA (0.84) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL3907654 | 0.78 | ESR1 (0.61) | CA7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070093473-A1 | 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | GLAXO GROUP LIMITED | 2007-04-26 | — | — | US | disclosed |
| EP-1687279-A1 | 7- [4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1663248-A1 | 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050261279-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2005051916-A1 | 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051397-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005025576-A1 | 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005016891-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005014578-A1 | PHENYLSULFONYL COMPOUNDS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | SIGMAR1, CBR3, CBR1 | MAOA 484/4885MAOB 291/4885SLC6A4 558/4885 |
| US-20050261279-A1 | Compounds | CBR1, CBR3, OXER1 | MAOA 2087/4885MAOB 2012/4885SLC6A4 3815/4885 |
| US-20070093473-A1 | 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | SIGMAR1, CHRNA3, CHRNA5 | MAOA 630/4885MAOB 444/4885SLC6A4 250/4885 |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | TPMT, HTR4, HTR7 | MAOA 1178/4885MAOB 484/4885SLC6A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.